AKT1 and hereditary clear cell renal cell carcinoma: The PI3K/AKT/mTor pathway is targeted by mTor inhibitors including everolimus, currently approved by the FDA for various cancers, including locally advanced, unresectable, or metastatic neuroendocrine tumors of pancreatic origin, and advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib (Fig. 5) [69].